<DOC>
	<DOCNO>NCT01457768</DOCNO>
	<brief_summary>This Registry design obtain long term data participant fail achieve sustain virologic response ( SVR ) receive least one Gilead oral antiviral agent ( OAV ) previous Gilead-sponsored hepatitis C virus ( HCV ) study .</brief_summary>
	<brief_title>A Gilead Sequence Registry Subjects Who Did Not Achieve Sustained Virologic Response</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Have previously participate Gileadsponsored hepatitis C study receive least one Gilead OAV Have fail achieve SVR previous Gileadsponsored study , define original treatment protocol Provide write , inform consent Be willing able comply visit schedule Individuals plan start new course hepatitis C therapy include investigational drug device course followup Registry History clinically significant illness major medical disorder may interfere followup , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>Registry</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>GS 9451</keyword>
	<keyword>GS 5885</keyword>
	<keyword>Sequence</keyword>
	<keyword>GS 5816</keyword>
	<keyword>GS 7977</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Sovaldiâ„¢</keyword>
	<keyword>SOF</keyword>
	<keyword>Ledipasvir</keyword>
	<keyword>LDV</keyword>
</DOC>